Case: 14-1324        Document: 19           Page: 1       Filed: 05/30/2014




             NOTE: This order is nonprecedential.


   United States Court of Appeals
       for the Federal Circuit
                      ______________________

            ENDO PHARMACEUTICALS INC.,
                Plaintiff-Cross-Appellant,

                                      v.

   MYLAN PHARMACEUTICALS INC. AND MYLAN
                    INC.,
            Defendants-Appellants.
            ______________________

                         2014-1324, -1365
                      ______________________

     Appeals from the United States District Court for the
 District of Delaware in No. 1:11-cv-00717-RMB-KW,
 Judge Renee Marie Bumb.

     ---------------------------------------------------------------------

            ENDO PHARMACEUTICALS INC.,
                  Plaintiff-Appellant,

                                      v.

   MYLAN PHARMACEUTICALS INC. AND MYLAN
                    INC.,
             Defendants-Appellees.
            ______________________

                                2014-1422
Case: 14-1324       Document: 19   Page: 2   Filed: 05/30/2014



 2   ENDO PHARMACEUTICALS INC.     v. MYLAN PHARMACEUTICALS



                    ______________________

     Appeal from the United States District Court for the
 District of Delaware in No. 1:11-cv-00717-RMB-KW,
 Judge Renee Marie Bumb.

                    ______________________

                        ON MOTION
                    ______________________
                Before NEWMAN, Circuit Judge.
                          ORDER
     Mylan Pharmaceuticals Inc. and Mylan Inc. (Mylan)
 move without opposition to reactivate and dismiss Appeal
 Nos. 2014-1324, -1365. Mylan also moves to dismiss
 certain portions of Endo Pharmaceuticals Inc.’s Appeal
 No. 2014-1422. Endo opposes dismissal of Appeal No.
 2014-1422.
     These appeals all stem from the same district court
 action. In Appeal No. 2014-1422, Endo appeals from the
 district court’s grant of Mylan’s Rule 60(b) motion, which
 vacated the judgment previously challenged in Appeal
 Nos. 2014-1324, -1365, as well as other orders. Mylan’s
 motion seeks to limit Endo’s appeal to the district court’s
 Rule 60(b) decision.
      No briefs have yet been filed in this appeal. We deem
 it the better course for Mylan to raise any issues concern-
 ing jurisdiction in its brief.
     Accordingly,
     IT IS ORDERED THAT:
    (1) Mylan’s motion to reactivate and dismiss Appeal
 Nos. 2014-1324, -1365 is granted.
Case: 14-1324    Document: 19     Page: 3   Filed: 05/30/2014



  ENDO PHARMACEUTICALS INC.   v. MYLAN PHARMACEUTICALS 3



    (2) Each party shall bear its own costs in Appeal Nos.
 2014-1324, -1365.
    (3) Mylan’s motion to dismiss Appeal No. 2014-1422 is
 denied.
     (4) The opening brief in 2014-1422 shall be due no lat-
 er than June 20, 2014.
                                    FOR THE COURT

                                    /s/ Daniel E. O’Toole
                                    Daniel E. O’Toole
                                    Clerk of Court


 ISSUED AS A MANDATE (As To 14-1324, -1365 Only):
 May 30, 2014

 s30
